
- 772 pages
- English
- ePUB (mobile friendly)
- Available on iOS & Android
eBook - ePub
Epigenetic Cancer Therapy
About this book
Epigenetic Cancer Therapy, Second Edition provides a comprehensive discussion of healthy and aberrant epigenetic biology, along with new discoveries to improve our understanding of cancer epigenetics and therapeutics. The book encompasses large-scale intergovernmental initiatives, as well as recent findings across cancer stem cells, rational drug design, clinical trials, and chemopreventative strategies. As a whole, the work articulates and raises the profile of epigenetics as a therapeutic option in the future management of cancer. Since the publication of the first edition of this book, the field of epigenetics has undergone significant change. New epigenetic therapies have been designed and approved for clinical use.
Our knowledge of the plasticity of the epigenome in cancer and disease has expanded dramatically, with increasing evidence linking pollution to epigenetic changes in cancer development. This second edition has been fully updated to address these changes, along with promising therapeutic programs such as CRISPR/Cas9 mediated approaches, CAR-T based therapies, epigenetic priming, histone modifications, and similar, transformative advances across synthetic biology and cellular engineering.
- Concisely summarizes the therapeutic implications of recent, large-scale epigenome studies
- Covers new findings in the interplay between cancer stem cells (CSCs) and drug resistance, thus demonstrating that epigenetic machinery is a candidate target for the eradication of these CSCs
- Provides a fully updated resource on new topics, including the epitranscriptome, oncohistones, single cell analysis, epigenetic priming, CRISPR therapy, CAR-T therapy, and epigenetics and pollution
- Features chapter contributions from leading experts in the field
Frequently asked questions
Yes, you can cancel anytime from the Subscription tab in your account settings on the Perlego website. Your subscription will stay active until the end of your current billing period. Learn how to cancel your subscription.
No, books cannot be downloaded as external files, such as PDFs, for use outside of Perlego. However, you can download books within the Perlego app for offline reading on mobile or tablet. Learn more here.
Perlego offers two plans: Essential and Complete
- Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
- Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, weâve got you covered! Learn more here.
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Yes! You can use the Perlego app on both iOS or Android devices to read anytime, anywhere â even offline. Perfect for commutes or when youâre on the go.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Yes, you can access Epigenetic Cancer Therapy by Steven Gray in PDF and/or ePUB format, as well as other popular books in Medicine & Oncology. We have over one million books available in our catalogue for you to explore.
Information
Table of contents
- Epigenetic Cancer Therapy
- Chapter 1 Introduction
- Chapter 2 Methylation and hydroxymethylation in cancer
- Chapter 3 Writers, erasers, and readers of DNA and histone methylation marks
- Chapter 4 Oncohistones
- Chapter 5 microRNA, epi-microRNA, and cancer
- Chapter 6 Long noncoding RNA in human cancers: to be or not to be, that is the question
- Chapter 7 The emerging roles of epitranscriptomic marks in cancer
- Chapter 8 Epigenomic profiling at genome scale: from assays and analysis to clinical insights
- Chapter 9 Environmental pollution, epigenetics, and cancer
- Chapter 10 Synthetic biology and cell engineeringâderiving new insights into cancer epigenetics
- Chapter 11 Epigenetic targeted therapies in hematological malignancies
- Chapter 12 Epigenetic therapy in lung cancer
- Chapter 13 Breast cancer epigenetics
- Chapter 14 Therapeutic applications of the prostate cancer epigenome
- Chapter 15 Neuroblastoma
- Chapter 16 Epigenetic therapiesâupdate on lysine methyltransferase/PRC complex inhibitors
- Chapter 17 Inhibitors of Jumonji-C domain-containing histone demethylases
- Chapter 18 Emerging epigenetic therapiesâlysine acetyltransferase inhibitors
- Chapter 19 Epigenetic therapies: histone deacetylases
- Chapter 20 Epigenetic intratumoral heterogeneity
- Chapter 21 Challenges for single-cell epigenetic analysis
- Chapter 22 Epigenetics of cisplatin resistance
- Chapter 23 Emerging epigenetic therapies: protein arginine methyltransferase inhibitors
- Chapter 24 Personalized epigenetic therapyâchemosensitivity testing
- Chapter 25 Epigenetic profiling in cancer: triage, prognosis, and precision oncology
- Chapter 26 Epigenetic primingâfact or falacy?
- Chapter 27 CRISPR, epigenetics, and cancer
- Index